Upload
colin-hancock
View
218
Download
0
Tags:
Embed Size (px)
Citation preview
Special Emphasis Pathway in Cancer BiologySpecial Emphasis Pathway in Cancer Biology
Paroxysmal Nocturnal Hemoglobinuria Paroxysmal Nocturnal Hemoglobinuria (PNH)(PNH)
Monica Bessler, MD, PhDWashington University School of Medicine St. LouisDivision of Hematology
Email [email protected]: http://bmf.im.wustl.edu
Bone Marrow Failure
Normal bone marrow Bone marrow failure
Bondurant et al.Wintrobe 1993
Hematopoiesis Occurs in the Bone Marrow
Acquired Inherited
Secondary bone marrow failure FanconiÕs anemia Radiation Dyskeratosis congenita (DC) Drug and chemicals (e.g. Benzene) Shwachman Diamond Syndrome Idiosyncratic reactions (e.g. Chloramphenicol) Diamond Blackfan Anemia (DBA) Virues (e.g. EBV, Hepatitis, CMV) Amegakaryocytic thrombocytopenia Immune diseases (e.g. Graft-versus-host disease) Severe congenital neutropenia Pregnancy Cartilage-Hair Hypoplasia Reticular Dysgenesis Idiopathic bone marrow failure Thrombocytopenia with absent radii Paroxysmal Nocturnal Hemoglobinuria (PNH) Pearson syndrome Non hematologic syndromes (e.g. DownÕs syndrome) Familial aplastic anemia
Causes of Bone Marrow Failure
Published by AAAS
C. Mayr et al., Science 315, 1576 -1579 (2007)
Fig. 1. Chromosomal translocations involving HMGA2, and the influence of let-7 on protein expression
F9
NIH 3T324hrs 48 hrs
oncogene
Tumor supressor
Let 7 tumor spressor
Published by AAAS
C. Mayr et al., Science 315, 1576 -1579 (2007)
Fig. 2. Luciferase reporter assays showing the influence of miRNA-target pairing
miRNA to let-7a
miRNA to mlet-7a
F9
NIH 3T3
HeLa
Published by AAAS
C. Mayr et al., Science 315, 1576 -1579 (2007)
Fig. 3. Soft-agar assay for anchorage-independent growth
NIH 3T3
Fig. S1
Paroxysmal Nocturnal Hemoglobinuria
I. Hemoglobinuria
II.Bone Marrow Failure
III.Thrombosis
Clinical Manifestations of PNH
Age Distribution of Patients with PNHAge Distribution of Patients with PNH
J Nishimura et. al. Medicine 2004
Tiananmen SquareTiananmen Square
Institute of Hematology & Blood Diseases HospitalChinese Academy of Medical ScienceTianjinChina
Peking Union Medical CollegeBeijingChina
Median Survival of Patients Diagnosed with PNH is 10 -15 Years
Thromboembolism in PNH
GPI-linked Proteins on Human Blood Cells
MonocytesB CellsT CellsNK CellsGranulocytesRed CellsPlateletsCD55CD58 1
CD59CD109(Gova/b-Ag)PrPcGP500
CD55 CD58 1
CD59 CD14 CD16 CD24(NAB1-Ag)CD48 CD66bCD66c CD87CD109 CD157LAP NB1 PrPc ADP-RTp50-80 GPI-80
CD55CD58 1
CD59CD14{CD16 2}CD48CDw52CD87CD109CD157Group-8PrPcGPI-80
CD55CD58 1
CD59CD24 CD48CDw52 {CD73}{CDw108}PrPc
CD55CD58 1
CD59{CD16 2} CD48CDw52{CD73}CD87{CD90}CDw108{CD109}PrPcADP-RT
CD55CD58 1
CD59CD16 2
CD48CDw52PrPc
HematopoieticStem Cell
CD59 CD109CD90
CD55, CD59(Cromer Ag)CD58, PrPc, AChE (Cartwrigt-Ag), CDw108(John-Milton-Hagen Ag)Dombroch residueHolley Gregory AG
Increased Sensitivity of Red Cells to Activated Complement
PNH Control
S HS S HSPNH patient
HamTest: 1938
Deficiency of GPI-Linked Proteins Deficiency of GPI-Linked Proteins on PNH-Granulocyteson PNH-Granulocytes
Diagnosis of PNH by Flow Cytometry
Patient
Control
Sideward scatter
CD59
Red Cells PMN Monocytes Lymph.
PNH red cells are of clonal origin
(Oni et al. 1970)
G6PD A
G6PD B
Female PNH Total RBCs
PNH RBCsMale normal RBCs
Male normal RBCs
GPI-Anchor
I
O OC=O
PEthN
P EthN
C-C-C
Man
GlcN
Man
P
Membrane
C=O
NH2
PEthN
Man
Protein
Phosphoethanolamine
P EthN
Man
GlcN
PI
Mannose
Glucosamine
Inositolphosphate
Pathway of GPI-anchor Biosynthesis
COOH COOH
NH 2
NH2
PIGSPIGTPIGUPIGKGAA1
DG
Ac
PIGL
DPM1DPM2DPM3MPDU1
GDP
GDP
Dol-P
Dol-P
PIGN
GlcNAcMan
PEth
PI
Ac
PIGAPIGCPIGHGPI1GPIPDMP2
?AcUDP UDP acetate
acyl-CoA
Dol-PDol-P
PIGB
PIGFPIGO DG
Endoplasmic reticulum
Dol-PDol-P
Dol-PDGPIGMPIGX
PIGW
PIGVGPI7
GPI-biosynthesis in PNH cell lines
[3H] mannose label
Block in the Pathway of GPI-anchor Biosynthesis
COOH COOH
NH 2
NH2
PIGSPIGTPIGUPIGKGAA1
DG
Ac
PIGL
DPM1DPM2DPM3MPDU1
GDP
GDP
Dol-P
Dol-P
PIGN
GlcNAcMan
PEth
PI
Ac
PIGAPIGCPIGHGPI1GPIPDMP2
?AcUDP UDP acetate
acyl-CoA
Dol-PDol-P
PIGB
PIGFPIGO DG
Endoplasmic reticulum
Dol-PDol-P
Dol-PDGPIGMPIGX
PIGW
PIGVGPI7
GPI-N-acetylglucosaminyltransferase
ER
P
I
P
I
Glc -NAc
NAc
PIGH
hGPI1Glc -NAc
NAc
UDP
PIGA
PIGC
PIGP
DPM2
PIGAPIGCPIGH
PIGPhGPI1
DPM2GPIQ?
Correction of the PNH Phenotype in LCL after PIGA
cDNA Tranfection
Anti-CD59-FITC
The PIGA Gene and the Mutations found in PNH
Luzzatto, 2000
PIGA maps to
the X-Chromosome
Major areas of investigationMajor areas of investigation
• Why does a PNH hematopoietic stem cell missing so many different proteins take over normal hematopoiesis ?
•What is the reason for clotting ?
• Can we design a more targeted treatment for patients with PNH ?
Erythroid Differentiation of PIGA- Erythroid Differentiation of PIGA- ES CellsES Cells
21 34 5 6
Cre
lacZ
loxP loxP
lacZ
loxPiga
wt Piga
Piga
Mouse Model for PNH
Blood Cells Deficient in Blood Cells Deficient in GPI-Linked ProteinsGPI-Linked Proteins
GPI-linked proteins
Granulocytes
Red cells∆ PIGA Control PNH Control
Mouse Human∆ PIGA
GPI-linked proteins
PNH Control∆ PIGA Control
S HS S HS(Heterologous SerumHS, Heat inactivated)
Acidified Serum Lysis Ham-Dacie - Test
Tremml et. al. 1999S HS S HS
PNH Blood Cells in Mouse and Man
GPI-linked marker
Lineagespecificmarker
Granulo-cytes
Red blood cells
MalePNH
FemalePNH
wtcontrol
Patient with PNH
Healthyindividual
Mouse Human
Red Blood Cells
0
20
40
60
80
100
1 2 4 8 12
Age (months)
% G
PI-
Ce
lls
Granulocytes
Age (months)
0
20
40
60
80
100
1 2 4 8 12
% G
PI-
Ce
lls
T Cells
0
20
40
60
80
100
1 2 4 8 12Age (months)
% G
PI-
Ce
lls
B Cells
0
20
40
60
80
100
1 2 4 8 12
Age (months)
% G
PI-
Ce
llsBlood Cells Deficient inBlood Cells Deficient in
GPI-Linked Proteins in Mice GPI-Linked Proteins in Mice
03/07
500
1000
2000
3000
8/93 1/99 5/00 9/01 2/03 6/04 11/05
AA PNH
Lac
tate
deh
ydro
gen
ase
(LD
H)
Normal range
ATG+Cy x3
Un
its
RB
C
12
84
Red cell transfusions
EculizumabEculizumabC5 blockadeC5 blockade
Case report: Case report: 31 year old female PNH patient # 9931 year old female PNH patient # 99
DVT
Hemolytic / Classical PNH AA/ PNH
PNHPNHPNH
Per
iphe
ral b
lood
ce
ll co
unt
Normal Normal Normal
Cytopenia
Relationship of PNH with Aplastic Anemia (AA)
Adapted from Rotoli & Luzzatto 1989
Trisomy 8 in MDS/PNH(Longo et. al. 1994)
Chromosome 8
Cytogenetic Abnormalities in PNH (Araten 2001)
U.P.N. Age % PNH Karyotypic abnormality
MSK 18 31M 7 47, XY, +6 [6/20] MSK 30 20M 5 47,X,+5,del(5)(q11.2)(6/15) MSK 8 57M 100 47,XY,+X[20/20]
MSK 20 16M 98 46,XY,t(17;19)(q11;q13)[6/20] MSK 17 42M 59 45,XY,-7[14/25] MSK 49 32M 36 47, XY+6[12/20] MSK 23 27M 70 46,XY,del(8p)[2/30] MSK 21 26M 82 47,XY,+8[2/20] MSK 19 63M 80 46,XY,del(5)(q15q31)[2/17] HH 56 19F 60 46,XX,del(13)(q12q14)[5/10]
MSK 16 45M 100 47,XY,+8[6/30]
Cytogenetic Abnormalities in PNHCytogenetic Abnormalities in PNH
PNH clone
Trisomy 8% B
lood
Cel
ls
Trisomy 8
PNH clone%B
lood
Cel
ls
%B
lood
Cel
ls
Trisomy 8
MDS within PNH PNH and MDS PNH within MDS
PNH clone
Leukemogenesis in PNH Mice After ENULeukemogenesis in PNH Mice After ENU
Leukemia in PNH mice
Tumor PNH WT Ovary (Adenoma) 3 1 Lung (Adenoma) 1 3 Adenocarcinoma 2 0
6/15 4/15
Leukemia
Myeloid hyperplasia in the bone marrow 2 2
Myeloid hyperplasia of the spleen 2 1
Liver infiltration 2 2 Parasternal infiltration 2 1 2/15 2/15
The Rate of Transformation is SimilarThe Rate of Transformation is Similarin AA and PNHin AA and PNH
MDS / AML in Patients with Aplastic Anemia (AA) Study Tichelli
(1988) DePlanqu e
(1989) Socie (1993)
Paquet te (1995)
Doney (1997)
Ohara (1997)
137 468 860 155 227 119 No of patients
% MDS / AML (Incidence) 7 1 (15-25) 4 2 (13) 10 (11) 10
MDS / AML in Patients with PNH
Study Hillmen (1995)
Socie (1995)
Spaet-Schwalbe (1995)
Moyo (2004)
Nishimura (2004) Japan Duke
Ware (1991)
Eibrink (2005)
80 220 40 49 209 176 49 11 No of patients
% MDS / AML (Incidence) 0 1 (5) 0 6 8 16 2 36
Possible Interrelationship Between PNH, Possible Interrelationship Between PNH, Aplastic Anemia, Myelodysplastic Syndrome,Aplastic Anemia, Myelodysplastic Syndrome,
and Acute Myeloid Leukemiaand Acute Myeloid Leukemia
PIGA(-) CellsNormal Cells
Normal MarrowNormal Marrow
Model for the Development of PNH Model for the Development of PNH
MutationPIGA(-) Cells + Second Hit MutationBM Injury
Adaptive MutationsAdaptive Mutations
Survival advantage hypothesisSurvival advantage hypothesis
PN
HP
NH
PN
HP
NH
Clinical OutcomeClinical Outcome
2 hit hypothesis2 hit hypothesis
BM InjuryBM Injury
Copyright ©2006 American Society of Hematology. Copyright restrictions may apply.
Inoue, N. et al. Blood 2006;108:4232-4236
Figure 3. Effects of the chromosome 12 abnormalities in 2 patients with PNH
Regulation of Ink4a/Arf during Aging
Tzatsos &Bardeesy Cell Stem Cell 2008
HMGA2 (a second factor for expansion of a PNH clone?)
• Expression of high mobility group AT-hook 2 (HMGA2), which is regulated by let-7 miRNAs (Mayr C et al, Science, 2007), contributes to proliferation of cells.
• Chromosomal abnormalities involving in HMGA2, which remove let-7-complementary sites in 3’-untranslated region (UTR), have been reported in patients with PNH (Inoue N et al., Blood, 2006) and related disorders including myeloproliferative disorders (Guglielmelli P et al., Stem Cells, 2007) and AML with myelodysplasia (Odero MD et al., Leukemia, 2005).
Mouse HMGA2
cDNABC052158
Complementary sites of let-7a
1 3 4 52 6 7
Introduction of truncated cDNA clone of Hmga2 into pPGKPuro
( )
5’-UTR 3’-UTRcoding
XhoI ClaI
Coding5’-UTR PGK-PAPGK-PROM
Specific primer pair
SalISalI
XhoI
ClaI
SalI
SalI
Replace puro with the truncated cDNA of Hmga2
Cleaved recombinant with SalI for injection
Homologous recombination for conditional truncation of Hmga2 3’-UTR
loxP
QuickTimeý DzTIFFÅiàèkǻǵÅj êLí£ÉvÉçÉOÉâÉÄ
ǙDZÇÃÉsÉNÉ`ÉÉǾå©ÇÈǞǽDžÇÕïKóvÇ ÇÅB
Exon 1 2 3 4 5
wt Hmga2
QuickTimeý DzTIFFÅiàèkǻǵÅj êLí£ÉvÉçÉOÉâÉÄ
ǙDZÇÃÉsÉNÉ`ÉÉǾå©ÇÈǞǽDžÇÕïKóvÇ ÇÅB
IRES/NEO-lox-Hmga2
loxP
IRES/NEO
0
0.2
0.4
0.6
0.8
1
1.2
1.4
BM Spleen Thymus Liver
TG (n=3 or 4)
WT (n=3)
qRT-PCR
Western Blotting
Actin
HMGA2
TG WTSpleen
TG WTThymus
TG WTLiver
TG WTBM
Expression of Hmga2 in Truncated-Hmga2+ TG mouse
Re
lativ
e e
xpre
ssio
n
P<0.05 P=0.0509
P<0.01
P<0.02
42 kDa
17 kDa
Peripheral blood count
• Age- and sex-matched 19 truncated Hmga2+ TG and wild-type BL6 mice
Competitive repopulation assay
Truncated-Hmga2+
(CD45.2)PEP
(CD45.1)
Donors
1. 50% vs 50%2. 10% vs 90%3. 100% vs 0%
vs
5 x 106 cells
Recipients PEP
Total 1000 radInjection
(BM transplantation; BMT)
Observe chimerisms of PB cells 6 weeks and 10 to 12 weeks after BMT
Prepare BM cells
0
10
20
30
40
50
606w (n=2)
12w (n=3)
Proportions of donor-derived cells after competitive repopulation assay
10% Hmga290% Recipient
50% Hmga250% Recipient
%C
D4
5.2+
ce
lls
Granulocytes Monocytes B cellsT cells
100% Hmga2
Granulocytes Monocytes B cellsT cells
Granulocytes Monocytes B cellsT cells
Truncated-Hmga2+/-
X Piga-
with 1% GPI-
60% GPI- etc.
Truncated-Hmga2+/-Piga-Piga- (without truncated Hmga2)
Breed truncated Hmga2+ mice with Piga- mice to see effect of Hmga2 on growth advantage of PNH
hematopoietic cells
• Time courses of changes in proportion of GPI- cells• Blood cell count• Competitive repopulation assay• Spontaneous or ENU-induced leukemogenesis
2 mice 1 mouse(need more breeding)
AcknowledgementsAcknowledgementsWashington University St. Louis:Kazu IkedaJeffrey HickenMarek JasinskyPeter Keller Bing Han Ike PantazopoulosShashikant KulkarniPhilip J. Mason Division of HematologyMorey BlinderJoshua Fields
Bone Marrow Transplant TeamJohn DiPersioPeter Westervelt
Hereditary Cancer CoreChissie KampJennifer Ivanovich
Division of RheumatologyCelia Fang John Atkinson
Dept. PathologyRichard BurackSusan Treese
Center for Clinical StudiesParticipating Medical CentersForTRIUMPHSEPHEREDEMBRACE
All patients with PNH for participating